MilliporeSigma Awards Grant to Combined Therapeutics for its Nucleic Acid Platform That, with Virotherapy, Targets Liver Cancer
MilliporeSigma today announced that Combined Therapeutics Inc., Cambridge, Massachusetts, has been selected as the North American winner of its 2020 Advance Biotech Grant Program
- Nucleic acid platform combined with virotherapy targets cancerous cells while protecting healthy tissue of key organs
- Company to receive in-kind MilliporeSigma products, consultation in downstream processing, formulation excipients and sterile filtration
MilliporeSigma today announced that Combined Therapeutics Inc., Cambridge, Massachusetts, has been selected as the North American winner of its 2020 Advance Biotech Grant Program. The biotechnology company was selected for its innovative nucleic acid platform which, combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system.
“We help pioneering biotech companies bring lifesaving drugs to market, faster,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “Combined Therapeutics’ platform shows promise to treat liver cancer, which affects thousands of people across the world each year.”
As part of the award, Combined Therapeutics Inc. will receive in-kind MilliporeSigma products and consultation in downstream processing, formulation excipients and sterile filtration.
Combined Therapeutics Inc. is in pre-clinical development of a platform to treat cancer by targeting solid tumors while protecting the healthy tissue of key organs. Virotherapy is treatment that uses a modified virus to target and destroy cancer cells. However, this approach can often lead to low patient response and safety concerns due to poor targeting. Combined Therapeutics aims to direct and enhance virotherapies while preventing off-target effects. With its potential to target specific cells only, this combined approach shows promise to be a safe and effective therapy for cancer.
“MilliporeSigma’s expertise in large biomolecule filtration, scale-up and extensive range of excipients will play a pivotal role in moving this project forward to GMP and clinical trials,” said Romain Micol, CEO, Combined Therapeutics Inc. “We are honored to have been selected as the winner of MilliporeSigma’s Advance Biotech Grant, and we look forward to the collaboration.”
Since 2014, MilliporeSigma’s Advance Biotech Grant Program has awarded technologies and consultation to 28 biotechnology companies. These grants have been used to support biotech companies whose missions are to help patients suffering from cancer, brain tumors, osteoarthritis and cardiovascular disorders.
To learn more about the program, visit: www.emdmillipore.com/emergingbiotech.
Downloads
-
Advanced-biotech-grant-Combined-Therapeutics-US.pdf
-
Advance-Biotech-Grant.jpg
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Combined Therapeutics Inc.
Combined Therapeutics Inc. (CTx) is a pre-clinical-stage biotech in the game-changing segment of cancer research that is immunotherapy. The company is converging nanomedicine and biotechnology to enhance the tumoral cells and the tumoral microenvironment targeting. Based in Cambridge, MA, Combined Therapeutics Inc. (CTx) is an immuno-oncology spin-out from the Massachusetts Institute of Technology.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.
Related News
-
Press Releases
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO (contract testing, development and manufacturing organization) to offer integrated services
2023/09/26